The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

Around 3,000 deaths and 5,500 hospital admissions in England caused by chronic heart failure could be prevented each year following our updated draft guideline on medical treatment of the disease.

Around 20,000 children and young people with type 1 diabetes in England now benefit from life-changing 'artificial pancreas' technology, recommended by NICE.

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone. These cookies remember ...

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 Nivolumab plus ipilimumab for ...

Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (terminated appraisal) TA1068 29 May 2025 29 May 2025 ...

Date Update 09 June 2025 The resolution start date for this topic has been delayed. The revised timeline for the evaluation will be available on the topic webpage in due course.

NICE has today (10 th June) published final draft guidance which recommends several treatment options for around 25,000 people with moderate rheumatoid arthritis that have not responded to ...

Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant [ID6468] Technology appraisal guidance Venetoclax with ibrutinib for treating ...

This guideline covers diagnosing and treating an aneurysmal (caused by a ruptured aneurysm) subarachnoid haemorrhage and its complications. It provides recommendations to improve diagnosis and ensure ...

1.1 Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if: 1.2 This recommendation is not intended to affect ...

The treatment, called relugolix–estradiol–norethisterone (also known as relugolix combination therapy or Ryeqo), works by blocking specific hormones that contribute to endometriosis, while also ...